Prudential PLC lessened its position in Hutchison China MediTech Limited (NASDAQ:HCM) by 1.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,230,838 shares of the company’s stock after selling 37,885 shares during the quarter. Prudential PLC’s holdings in Hutchison China MediTech Limited were worth $52,001,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new stake in Hutchison China MediTech Limited during the first quarter valued at about $618,000. Baillie Gifford & Co. lifted its stake in Hutchison China MediTech Limited by 2.7% during the first quarter. Baillie Gifford & Co. now owns 157,892 shares of the company’s stock worth $3,150,000 after purchasing an additional 4,189 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Hutchison China MediTech Limited during the second quarter worth about $5,102,000. Matthews International Capital Management LLC lifted its stake in Hutchison China MediTech Limited by 159.7% during the first quarter. Matthews International Capital Management LLC now owns 263,400 shares of the company’s stock worth $5,255,000 after purchasing an additional 161,971 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in Hutchison China MediTech Limited by 7.4% during the first quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock worth $10,190,000 after purchasing an additional 35,053 shares during the last quarter. 4.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Hutchison China MediTech Limited (NASDAQ HCM) traded down 2.58% on Wednesday, hitting $29.88. The stock had a trading volume of 39,434 shares. Hutchison China MediTech Limited has a 12 month low of $10.61 and a 12 month high of $32.03.

HCM has been the subject of a number of recent research reports. Canaccord Genuity set a $30.00 price objective on shares of Hutchison China MediTech Limited and gave the stock a “buy” rating in a report on Tuesday, June 6th. BidaskClub lowered shares of Hutchison China MediTech Limited from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Hutchison China MediTech Limited currently has a consensus rating of “Hold” and a consensus target price of $28.00.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/04/prudential-plc-cuts-position-in-hutchison-china-meditech-limited-hcm.html.

Hutchison China MediTech Limited Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hutchison China MediTech Limited (NASDAQ:HCM).

Institutional Ownership by Quarter for Hutchison China MediTech Limited (NASDAQ:HCM)

Receive News & Stock Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related stocks with our FREE daily email newsletter.